How long should pindolol be associated with paroxetine to improve the antidepressant response?

Journal of Clinical Psychopharmacology

Volumn 17, Issue 6, 1997, Pages 446-450

  Zanardi, Raffaella ^b   Artigas, Francesc ^a   Franchini, Linda ^c   Sforzini, Laura ^c   Gasperini, Mariangela ^c   Smeraldi, Enrico ^c   Perez, Jorge ^c  

^a INST D INVESTIGACIONS B   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PAROXETINE; PINDOLOL; PLACEBO; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR;

ADULT; ANXIETY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOMNOLENCE; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PAROXETINE; PINDOLOL; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0031396455     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199712000-00002     Document Type: Article

References (19)

1. Anderson A, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8: 238-49.
2. Artigas F. 5-HT and antidepressants: new views from microdialysis studies [letter]. Trends Pharmacol Sci 1993;14:262.
3. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-5.
4. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
5. Blier P, Bergeron R. Effectiveness of pindolol with selected anti-depressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-22.
6. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997;154:37-43.
7. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349: 1594-7.
8. 1A antagonists. Trends Neurosci 1996;19:378-83.
9. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentration of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn Schmiedebergs Arch Pharmacol 1996;353:630-40.
10. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. Martindale W. Extra pharmacopoeia London: Pharmaceutical Press, 1993.
12. Levin J, Guy W, eds. ECDEU assessment manual. Rockville, MD: US Department of Education and Welfare, National Institute of Mental Health Research, 1976.
13. Cox DR. Regression models and life-tables. J R Stat Soc 1981;34:187-220.
14. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996;15:349-60.
15. Tomé MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-9.
16. Howland RH. Biochemical effects of antidepressant augmentation [letter]. Arch Gen Psychiatry 1995;52:156.
17. Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch Gen Psychiatry 1995;52:969-71.
18. 1B autoreceptor blocking properties of the beta adrenoreceptor antagonist (-)penbutolol. J Pharmacol Exp Ther 1993;265:707-12.
19. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986;255:357-60.